RONA Therapeutics

RONA Therapeutics develops oligonucleotide therapeutics to treat metabolic diseases, neurological diseases, and ophthalmology conditions. The company focuses on the discovery and development of modular and programmable RNA medicines using proprietary delivery systems that enable targeted delivery of RNA-based therapeutics to specific tissues and cell types. Founded in 2021 and headquartered in Shanghai, China, RONA Therapeutics has raised $68M in Series A funding from investors including LongRiver Investments, BioTrack Capital, Lilly Asia Ventures, CMB International Capital, Fontus Capital, and LanTing Capital. The company employs 19 people and leverages advances in RNA chemistry and delivery technology to develop therapeutics that can modulate gene expression with high specificity, addressing diseases where traditional small molecule and antibody drugs have limited efficacy.